While these studies support an oncogenic effect of PPARα in RCC, the molecular mechanisms of tumorigenesis by PPARα and a potential therapeutic approach of PPARα inhibition have not been evaluated in RCC. The gene discussed is PPARA; the disease is renal cell carcinoma.